Stealth Biotherapeutics Corp Ads
Stealth Biotherapeutics Corp Ads (MITO) on the NASDAQ Exchange
Company overview
Stealth Biotherapeutics Corp Ads is a publicly listed company from USA with shares traded on NASDAQ under the ticker MITO. This page provides a live view of market pricing and an interactive chart to follow short and long-term moves without manual refresh. The latest streaming quotes for MITO are bid 0.32 USD and ask 0.32 USD.
Use the chart to review recent momentum, identify key price areas, and track how Stealth Biotherapeutics Corp Ads is performing relative to your portfolio in 2025. If you are researching the instrument for trading or investing, add MITO to your watchlist in R StocksTrader and compare it with other US and European shares, indices, and metals.
Key facts
- Exchange: NASDAQ
- Company: Stealth Biotherapeutics Corp Ads
- Ticker: MITO
- Country: USA
- Bid: 0.32 USD
- Ask: 0.32 USD
- Quotes: real-time, auto-updated
Risk
Risk Warning: Past performance of MITO does not predict future returns.
FAQ
Open a trading account at RoboForex, decide on the number of assets to buy, and then place an order for Stealth Biotherapeutics Corp Ads (MITO) in R StocksTrader. Create and verify your profile, fund the account, search for MITO, and choose the instrument type available to you. Add MITO to your Watchlist to track moves and manage open positions throughout 2025.
MITO trades on NASDAQ and is issued by Stealth Biotherapeutics Corp Ads. This page provides a live chart and continuously updated price data for the 2025 year so that you can follow intraday swings and longer trends. Before starting trading and placing orders, review trading hours, typical spreads, and fees in the terminal to make sure conditions for MITO match your plan.
Quotes update automatically in real time. Current levels for MITO are bid 0.32 USD and ask 0.32 USD. The spread is the difference between ask and bid and affects your effective entry and exit. Track MITO in R StocksTrader and adjust your approach as market conditions change in 2025.